Introduction {#sec1_1}
============

In 1982, Gass and Oyakawa \[[@B1]\] described idiopathic macular telangiectasia (IMT) as a condition involving capillary ectasia and dilation in the juxtafoveal region. Clinical presentation comprises decreased visual acuity, sometimes accompanied by metamorphopsia, as well as a central scotoma, as the disease slowly progresses.

According to the classification by Gass and Blodi \[[@B2]\], there are 3 types of IMT (table [1](#T1){ref-type="table"}). Type 1 (IMT-1): unilateral macular telangiectasia with visible aneurysms, which occurs predominantly in males; in this case, the cause of visual loss is mostly macular edema \[visible and exudative IMT (IMT-1A); visible, exudative and focal IMT (IMT-1B)\]. Type 2 (IMT-2): bilateral macular telangiectasia that occurs in men and women, with characteristic features on multimodal imaging \[[@B3]\]; subretinal or intraretinal neovascularization is frequently seen in this type \[occult and nonexudative IMT (IMT-2A); juvenile, occult and familial IMT (IMT-2B)\]. Type 3 (IMT-3): very rare, associated with vascular occlusions, occurring in the larger setting of a medical or neurological disease \[occlusive IMT (IMT-3A); occlusive IMT associated with central nervous system vasculopathy (IMT-3B)\].

Moreover, in 2006, Yannuzzi et al. \[[@B4]\] merged the IMT-1 subtypes into one group of aneurysmal telangiectasia, characterized by clearly visible aneurysms, and defined IMT-2A as a group of perifoveal telangiectasia, leaving out IMT-2B and IMT-3 because of their rarity. In addition, they described the possible association of IMT-2 with retino-retinal anastomosis and choroidal neovascularization \[[@B4]\].

The therapeutic options for IMT-1 consist of laser photocoagulation, which is the main treatment, as well as intravitreal injections (IVTs) of steroids or anti-vascular endothelial growth factor (anti-VEGF) agents \[[@B3]\].

Several associations have been found between the IMT and other vascular anomalies \[[@B5]\]. The case we report combines the characteristics of IMT-1A with the intraretinal vascular complex typical of a type 3 neovascularization.

Case Report {#sec1_2}
===========

An 85-year-old woman presented at our clinic complaining of gradual vision loss in her left eye (LE). Her past medical history included well-controlled arterial hypertension. Her best-corrected visual acuity (BCVA) was 20/80 in the right eye (RE) and 20/200 in the LE. The anterior segment examination was unremarkable. Fundus examination of the RE was unremarkable, while for the LE, it revealed 2 small hemorrhages located nasally to the fovea accompanied by lipid exudates inferiorly and superiorly (fig. [1](#F1){ref-type="fig"}).

Early-phase fluorescein angiography (FA; Spectralis, SD-OCT+HRA, Heidelberg Engineering, Germany) was unremarkable in the RE, while it demonstrated dilated capillaries within the LE fovea, along with vascular tortuosity in the superior and nasal macula (fig. [2a](#F2){ref-type="fig"}). Early FA of the LE also showed a zone of focal hyperfluorescence with a superotemporal right-angle dilated feeding vessel, deepening into the foveal avascular zone, evocative of a type 3 intraretinal neovascularization (fig. [2a](#F2){ref-type="fig"}). Spectral-domain optical coherence tomography (SD-OCT; Spectralis) of the RE showed an epiretinal membrane along with a discrete vitreomacular traction. SD-OCT of the LE revealed small, round, well-demarcated foveal lesions with hyperreflective edges in the inner retinal layers, corresponding to microaneurysms along with cystoid spaces. A hyperreflective lesion located in the outer retinal layers, temporal to the macula and adherent to the retinal pigment epithelium \[[@B6], [@B7]\], indicating the presence of type 3 intraretinal neovascularization, was also noted (fig. [2b](#F2){ref-type="fig"}). Indocyanine green angiography (ICGA; Spectralis) revealed a late hyperfluorescence and confirmed the presence of a type 3 neovascularization in the LE (fig. [2c](#F2){ref-type="fig"}).

Based on these findings, the patient was diagnosed with atypical IMT-1 (the average age at presentation of patients in this group is 37 years \[[@B2]\]) and coincident type 3 neovascularization. The patient was treated with a series of 3 monthly IVTs of ranibizumab (0.5 mg/0.05 ml) in the LE followed by a prn regimen.

At 6 months, after 3 ranibizumab IVTs, BCVA improved to 20/160 in the LE. FA and ICGA showed absence of late-phase leakage from the lesion, and SD-OCT revealed regression of the exudative signs (fig. [2d](#F2){ref-type="fig"}). SD-OCT revealed recurrence of exudative signs at 8 months, and thus, the patient received repeated ranibizumab IVTs on a monthly basis up to month 14 (6 IVTs). At month 16, due to recurrence of exudative signs, the patient received repeated ranibizumab IVTs on a monthly basis up to month 22 (6 IVTs). At 24 months, after a total of 15 IVTs, BCVA improved to 20/100 in the LE, and FA, ICGA and SD-OCT showed regression of both cystoid macular edema and serous retinal detachment.

Discussion {#sec1_3}
==========

We described the case of a patient diagnosed with atypical IMT-1A associated with type 3 neovascularization. According to the classification by Gass and Blodi \[[@B2]\], the presence of a unilateral telangiectatic lesion accompanied by microaneurysms would suggest the diagnosis of IMT-1A. Nevertheless, the association of macular telangiectasia with a type 3 intraretinal neovascularization is a typical complication of IMT-2 and is known to be a sign of exudative age-related macular degeneration \[[@B8], [@B9]\]. To our knowledge, the shared characteristics between IMT-1 and IMT-2 have only been described once in a similar case in 2011, by Mezad-Koursh et al. \[[@B10]\]. Given the unusual association observed, our cases, along with the case described by Mezad-Koursh et al. \[[@B10]\], are evocative of a new subtype of IMT that we propose to call IMT-1C, characterized by unilateral macular telangiectasia with visible aneurysms and macular edema, possibly complicated by type 3 neovascularization. This subtype of IMT seems responsive to anti-VEGF treatments. The description of more cases of IMT-1C is desirable in order to define this subtype of IMT.
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![Color fundus photograph of the LE in an 85-year-old patient with IMT-1 associated with type 3 neovascularization, presenting 2 small hemorrhages nasally to the fovea (arrow), accompanied by lipid exudates (open arrowheads).](cop-0005-0352-g01){#F1}

![Multimodal imaging in an 85-year-old patient showing IMT-1 associated with type 3 neovascularization. **a** Early-phase FA at baseline showing hyperfluorescent lesions nasally to the fovea, corresponding to the dilated capillaries (arrow), and a zone of focal hyperfluorescence with a superotemporal right-angle dilated feeding vessel, deepening into the foveal avascular zone (curved arrow), evocative of a type 3 intraretinal neovascularization. **b** SD-OCT at baseline showing small, round, well-demarcated foveal lesions with hyperreflective edges, corresponding to microaneurysms, along with cystoid spaces (arrow). A hyperreflective lesion located in the outer retinal layers, adherent to the underlying retinal pigment epithelium, indicates type 3 intraretinal neovascularization (arrowhead). **c** Late-phase ICGA at baseline showing a focal hyperfluorescence (arrowhead), corresponding to the intraretinal complex of type 3 neovascularization. **d** Six-month follow-up SD-OCT revealing the disappearance of both the cystoid macular edema and serous retinal detachment.](cop-0005-0352-g02){#F2}

###### 

Epidemiological and clinical features of IMT, according to the classification by Gass and Blodi \[[@B2]\]

                                     IMT type                                                                       
  ---------------------------------- -------------------- ------------ --------------- ---------------- ----------- -----------------------------------------
  Frequency                          Second most common   Rare         Most common     Extremely rare   Very rare   Very rare
  Gender                             Male (90%)           Male         Male = female   Male = female    Female      Male = female
  Age, years                         15--54               Middle age   35--65          35--65           40--60      Middle age
  Congenital/acquired                Congenital           Congenital   Acquired        Acquired         Acquired    (?)
  Laterality                         Unilateral           Unilateral   Bilateral       Bilateral        Bilateral   Bilateral
  Microaneurysms or telangiectasia   +++                  \+           --              --               \+          \+
  Yellow exudates                    \+                   +/--         --              --               Minimal     Minimal
  Subretinal neovascularization      --                   --           \+              \+               --          --
  Capillary occlusion                Minimal              --           --              (?)              +++         +++
  Systemic associations              --                   --           --              --               --          Central nervous system vasculopathy (?)
